# Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/bevacizumab-plus-erlotinib-combination-therapy-for-advanced-hereditary/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yeonjoo Choi,Bhumsuk Keam,Miso Kim,Shinkyo Yoon,Dalyong Kim,Jong Gwon Choi,Ja Young Seo,Inkeun Park,Jae‐Lyun Lee |
| Citations | 62 |
| DOI | 10.4143/crt.2019.086 |
| Fields | Medicine |
| Open Access | true |
| OA Status | diamond |
| OA URL | http://www.e-crt.org/upload/pdf/crt-2019-086.pdf |
| OpenAlex ID | https://openalex.org/W2963695239 |
| PMID | 30913859 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Yeonjoo Choi](https://scholariq.org/researchers/yeonjoo-choi/)
- [Shinkyo Yoon](https://scholariq.org/researchers/shinkyo-yoon/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)
- [Bladder and Urothelial Cancer Treatments](https://scholariq.org/topics/bladder-and-urothelial-cancer-treatments/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.